1Kyle RA, Maldonado JE, Baynd ED. Plasma cell leukaemia: report on 17 cases. Arch Intern Med, 1974,133:813-818.
2Noel P,Kyle RA. Plasma cell leukaemia:an evaluation of response to therapy. Am J Med, 1987,83:1062-1069.
3Regis C, Daniele S, Reda B, et al. Primary plasma cell leukaemia: a report of 18 cases. Leuk Res, 2001,25:103-107.
4Garcia-Sanz BR, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood, 1999,93:1032-1037.
5Bernasconi C, Castelli G, Pagnucco G, et al. Plasma cell leukaemia:a report of 15 patients. Eur J Haematol,1989,51Suppl:76-77.
6Vela-Ojeda J, Garcia-Ruiz Esparza MA, Rosas-Cabral A,et al. Intermediate doses of melphalan and dexamethasone better than vincrstine,adriamycin, and dexamethasone(VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol, 2002, 81:362-367.
7Hovenga S, de Wolf JT, Klip H, et al. Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD,high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature. Bone Marrow Transplant, 1997,20:901-904.
8Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 1999,341:1565-1571.
9Hideshima T, Chauhan D, Podar K, et al. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol,2001,28:607-612.
10Strasser K, Ludwig H. Thalidomide treatment in multiple myeloma.Blood Rev,2002,16: 207 -215.
